AZN — AstraZeneca PLC
Is AZN overbought or oversold? Here is the current MarketMoodz read.
AstraZeneca PLC (AZN) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $156.91. The rating moved from Overbought to Oversold on October 1, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$156.91
- Last changeMoved from Overbought to Oversold on October 1, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
See all oversold Healthcare stocks →
AI analysis
AstraZeneca's broad therapeutic footprint, late-stage biologics pipeline and recent collaboration activity provide a constructive growth backdrop and defensive appeal amid short-term market risk aversion. Near-term upside is supported by stable cash flow, global commercialization scale and investor interest in specialty biologics, while policy headwinds and escalating competitive innovation in metabolic therapies create tangible pricing and market-share pressures.
Key factors
- Diversified global pharma portfolio with meaningful exposure to oncology, respiratory, and specialty medicines, supporting resilient revenue streams
- Active late-stage biologics and specialty pipeline that sustains medium-term growth optionality and investor interest in conviction biotech plays
- Defensive sector positioning likely to attract flows in near-term risk-off environment, supporting price stability and upside
- Recent collaboration disclosure (AZ & DS collaboration with Summit for Datroway) signals ongoing business development and pipeline expansion
- Strong commercial footprint and scale that provide pricing and distribution advantages across major markets
- Solid free-cash-flow generation and balance-sheet flexibility to fund M&A, R&D and shareholder returns (dividends/repurchases) relative to peers
Risks
- Heightened policy and payer pressure (Medicare drug-price negotiation / IRA) that could compress pricing and margins for higher-cost therapies
- Competitive intensity from GLP-1 / amylin combos and other class innovations that can reshape market share and pricing dynamics in metabolic/weight markets
- Regulatory or clinical setbacks in late-stage programs that would impair near-term catalysts and valuation
- Supply-chain or manufacturing disruptions (global geopolitical uncertainty) that can affect product availability and revenue timing
- Currency volatility given multinational revenues and cost bases
- Commercial execution risk in key markets and potential loss of exclusivity for legacy products
- Market-wide risk-off sentiment which can limit upside without fresh company-specific catalysts
Latest MarketMoodz coverage
- Abbisko and AstraZeneca Launch NSCLC Combo Trial After China IND2026-07-02
- AstraZeneca Advances Rare-Bone Drug as Enhertu Wins EU Tumor‑Agnostic Label2026-06-29
- AstraZeneca Wins FDA Nod for Truqap, Opens Targeted Prostate Market2026-06-15
- AstraZeneca’s Oral GLP‑1 Pill Moves to Phase 3, Threatening Injectable Dominance2026-06-09
- Ultomiris Slashes Proteinuria in IgA Nephropathy; AstraZeneca Eyes New Indication2026-06-08
See today's live rating, score and targets
Members see the live hourly rating for AZN — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.